

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/968,208	11/12/1997	RUSSELL HIGUCHI	9397	8271	
22896	7590 09/03/2004		EXAMINER		
MILA KASAN, PATENT DEPT. APPLIED BIOSYSTEMS			SNAY, JEFFREY R		
850 LINCOLN CENTRE DRIVE			ART UNIT	PAPER NUMBER	
FOSTER CITY, CA 94404			1743		
			DATE MAILED: 09/03/2004	DATE MAILED: 09/03/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

Supplemental				
Notice of Allowability				

Application No.	Applicant(s)		
08/968,208	HIGUCHI, RUSSELL		
Examiner	Art Unit		
Jeffrey Snay	1743		

Nation of Allege Lille	00/300,200	THOUGHI, NOOSELL	
Notice of Allowability	Examiner	Art Unit	
	Jeffrey Snay	1743	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.31	(OR REMAINS) CLOSED in this a or other appropriate communication (IGHTS). This application is subject	pplication. If not included on will be mailed in due course. 1	ΓΗΙ S nitiative
1. $igspace$ This communication is responsive to <u>a telephone conferer</u>	nce held September 1, 2004.		
2. 🔀 The allowed claim(s) is/are <u>30, 31, 35-37, 48, 39-40, 44-4</u>	6 and 49; renumbered 1-12, respec	tively.	
3. $igotimes$ The drawings filed on <u>17 March 2004</u> are accepted by the	Examiner.		
4. Acknowledgment is made of a claim for foreign priority u a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give 6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspers 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date (b) including changes required by the attached Examiner' Paper No./Mail Date 1. DEPOSIT OF and/or INFORMATION about the deponant attached Examiner's comment regarding REQUIREMENT	e been received. e been received in Application No. cuments have been received in this of this communication to file a reply MENT of this application. Initted. Note the attached EXAMINER es reason(s) why the oath or declar at be submitted. Son's Patent Drawing Review (PTC) as Amendment / Comment or in the .84(c)) should be written on the draw the header according to 37 CFR 1.121 sit of BIOLOGICAL MATERIAL	s national stage application from a complying with the requirement of the complying of the c	ts
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/O Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ☐ Interview Summar Paper No./Mail Da 08), 7. ☒ Examiner's Amend	Patent Application (PTO-152) (PTO-413), ate ment/Comment ent of Reasons for Allowance Jill A. Warden SPE Art Unit: 1743	

Art Unit: 1743

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Vincent Powers on September 2, 2004.

The application has been amended as follows:

After discussions with applicants' representative on the meaning of "thermal cycler", applicants' representative and Examiner Warden agreed to amend the independent claims to recite an "automated thermal cycler" in order to resolve any ambiguity. Previously cancelled claims 38 and 47 are being reinstated as new claims 48 and 49 because computer control is not required by such automation. A minor correction is also being made to claim 36.

A complete listing of the claims is attached hereto.

Any inquiry concerning this communication should be directed to Jill A. Warden at telephone number (571) 272-1267.

Jill A. Warden

ر Art Unit 1743

AMENDMENT

Listing of the Claims (new text is underlined, deleted text is bracketed)

1-29. (Canceled)

- 20. (Currently Amended) An instrument for use in monitoring a nucleic acid amplification reaction comprising multiple thermal cycles, comprising:
- (a) [a] an automated thermal cycler capable of alternately heating and cooling, and adapted to receive, at least one reaction vessel containing an amplification reaction mixture comprising a target nucleic acid, reagents for nucleic acid amplification, and a detectable nucleic acid binding agent; and
- (b) a detector operable to detect a fluorescence optical signal while the amplification reaction is in progress and without opening the at least one reaction vessel, which fluorescence optical signal is related to the amount of amplified nucleic acid in the reaction vessel.
- 2 31. (Previously Presented) The instrument of claim 36, wherein the thermal cycler is adapted to receive a plurality of reaction vessels, each containing an amplification reaction mixture.

32-34. (Canceled)

- 35. (Previously Presented) The instrument of claim 36, wherein the detector is operable to detect a fluorescence optical signal at a wavelength at or about 570 nm.
- 4 36. (Currently Amended) The instrument of claim 36, which includes a scaled <u>light</u> transmission path between the reaction vessel and the detector.
- 5 37. (Previously Presented) The instrument of claim 36, wherein the sealed light transmission path is a fiber optic cable.

38. (Canceled)

7 39. (Currently Amended) A system for use in monitoring a nucleic acid amplification reaction comprising multiple thermal cycles, comprising:

- (a) at least one reaction vessel adapted to contain an amplification reaction mixture comprising a target nucleic acid, reagents for nucleic acid amplification, and a detectable nucleic acid binding agent;
- (b) [a] an automated thermal cycler capable of alternately heating and cooling such a reaction vessel, and
- (c) a detector operable to detect a fluorescence optical signal while the amplification reaction is in progress and without opening the at least one reaction vessel, which fluorescence optical signal is related to the amount of amplified nucleic acid in the reaction vessel.
- 8 40. (Previously Presented) The system of claim 29, wherein the system comprises a plurality of reaction vessels, each adapted to contain an amplification reaction mixture.

41-43. (Canceled)

- 9 44. (Previously Presented) The system of claim 39, wherein the detector is operable to detect a fluorescence optical signal at a wavelength at or about 570 nm.
- 10 48. (Previously Presented) The system of claim 39, wherein the at least one reaction vessel includes a clear or translucent cap optically coupled to the detector by a sealed light transmission path.
- // 46. (Previously Presented) The system of claim 48, wherein the sealed light transmission path is a fiber optic cable.

47. (Canceled)

6 48. (New) The instrument of claim 30, wherein the thermal cycler is computer-controlled.

12 Mg. (New) The system of claim 39, wherein the thermal cycler is computer-controlled.